Monday, 02 October 2023
| COMMERCIAL PRODUCTS | THERAPEUTIC CATEGORY | STATUS |
|---|---|---|
| Clidinium Bromide | Anti-cholinergic | Commercial |
| Atropine Sulphate | Anti-cholinergic | Commercial |
| Homatropine Methylbromide | Anti-cholinergic | Commercial |
| Homatropine Hydrobromide | Anti-cholinergic | Commercial |
| Buprenorphine Base | Pain Management/De addiction | Commercial |
| Buprenorphine HCl | Pain Management/De addiction | Commercial |
| Naloxone HCl | Pain Management/De addiction | Commercial |
| Oxybutynin Chloride/ Hydrochloride | Anti-cholinergic | Commercial,CEP |
| Glycopyrrolate/Glycopyronium Bromide | Anti-cholinergic | Commercial |
| Glycopyrrolate/Glycopyronium Bromide - Micronised (D90 < 6 micron, D99 < 10 micron) | Anti-cholinergic Inhalation | Commercial |
| Isopropamide Iodide | Anti-cholinergic | Commercial |
| Pramoxine HCl | Topical Anaesthetic | Commercial |
| Naltrexone HCl | Pain Management/De addiction | Under Development |
| Etizolam | Anxiolytic | Under Development |
| Baclofen | Muscle Spasticity | Under Development |
| Prazepam | Anxiolytic | Under Development |
| Loprazolam | Anxiolytic | Under Development |
| Ipratropium Bromide | COPD, Asthma | Commercial |
| Clotiazepam | Anxiolytic | Under Development |
| Zolpidem Tartrate | Anxiolytic | Commercial |
| Midazolam | Hypnotics | Commercial |
